Literature DB >> 6732223

In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

T Barlam, H C Neu.   

Abstract

RU 28965, a novel macrolide antibiotic, inhibited most gram-positive species at concentrations similar to that of erythromycin but was not active, even at alkaline pH, against Pseudomonas spp. or members of the family Enterobacteriaceae. Staphylococci and streptococci resistant to erythromycin were resistant to RU 28965. RU 28965 inhibited Haemophilus influenzae, including a number of beta-lactamase, ampicillin-resistant isolates, and Neisseria meningitidis and Neisseria gonorrhoeae at concentrations similar to those of erythromycin. Against anaerobic species, Bacteroides fragilis and Clostridia and Fusobacterium spp., RU 28965 was less active than erythromycin, but its activity against Campylobacter and Legionella spp. was similar to that of erythromycin.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6732223      PMCID： PMC185573          DOI： 10.1128/AAC.25.4.529

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  In vitro activity of josamycin against aerobic gram-positive cocci and anaerobes.

Authors:  E L Westerman; T W Williams; N Moreland
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

2.  Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis.

Authors:  P C Fuchs; C Thornsberry; A L Barry; R N Jones; T L Gavan; E H Gerlach; H M Sommers
Journal:  J Antibiot (Tokyo)       Date:  1979-09       Impact factor: 2.649

Review 3.  Erythromycin.

Authors:  M J Gribble; A W Chow
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

4.  In vitro activity of midecamycin, a new macrolide antibiotic.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

5.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  Susceptibility of Pittsburgh pneumonia agent (Legionella micdadei) and other newly recognized members of the genus Legionella to nineteen antimicrobial agents.

Authors:  A W Pasculle; J N Dowling; R S Weyant; J M Sniffen; L G Cordes; G M Gorman; J C Feeley
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

7.  Susceptibility of Legionella pneumophila to twenty antimicrobial agents.

Authors:  P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191
  7 in total
  29 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

Review 2.  New directions for macrolide antibiotics: structural modifications and in vitro activity.

Authors:  H A Kirst; G D Sides
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965).

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

5.  In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

Authors:  J Chan; B J Luft
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

7.  Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.

Authors:  S Czinn; H Carr; S Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

8.  Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role.

Authors:  C Agen; R Danesi; C Blandizzi; M Costa; B Stacchini; P Favini; M Del Tacca
Journal:  Agents Actions       Date:  1993-01

9.  Pulmonary disposition of roxithromycin (RU 28965), a new macrolide antibiotic.

Authors:  J Chastre; P Brun; J B Fourtillan; P Soler; G Basset; C Manuel; J L Trouillet; C Gibert
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

10.  Disposition of roxithromycin in patients with normal and severely impaired renal function.

Authors:  C E Halstenson; J A Opsahl; M H Schwenk; J M Kovarik; S K Puri; I Ho; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.